Oragenics price to sales ratio OGEN

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 167×; Aug 2024
10-year median: 65.7×
10-year range: 21.9× to 199×
Peer median: 0.4×

Oragenics' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Aug 2024, at 167×.

On the days it had one over the last ten years, its median was 65.7×, from 21.9× in Nov 2016 to 199× in Jun 2024.

Price to sales ratio over time

median 65.7×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2024	167×	95.5×	199×
2023	82.8×	40.7×	82.8×
2022	n/m a value too high to mean anything
2021	n/m a value too high to mean anything
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	61.6×	54.7×	71.4×
2016	52.8×	18.7×	73.3×
2015	47.3×	23.9×	112×
2014	27.6×	25.1×	118×
2013	85.2×	50.6×	98.5×
2012	52.7×	10.9×	56.0×

Against its peers

Companies in Healthcare nearest Oragenics' size, closest first, today.

Company	Price to sales ratio
OGENOragenics	n/m
OXBROXBRIDGE RE HOLDINGS	2.8×
EDUCEducational Development	0.4×
GTIMGood Times Restaurants	0.1×
MDRRMedalist Diversified	1.6×
BCGBinah Capital	0.1×
Peer median	0.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Oragenics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.